Formulation of Modified Liquid-Solid Compact for Dissolution Enhancement of Raloxifene Hydrochloride.
Raloxifene hydrochloride (RLX), used in postmenopausal osteoporosis, is a class-II drug as per Biopharmaceutics Classification System. The purpose of this research was to formulate modified liquisolid compacts (MLSC) of RLX for improved dissolution in immediate-release tablet formulations. Prelimina...
| Publicado en: | Pharmaceutical Technology Europe Vol. 33; no. 7; pp. 20 - 25 |
|---|---|
| Autores principales: | , , , |
| Formato: | Journal Article |
| Publicado: |
MJH Life Sciences
Jul2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| Sumario: | Raloxifene hydrochloride (RLX), used in postmenopausal osteoporosis, is a class-II drug as per Biopharmaceutics Classification System. The purpose of this research was to formulate modified liquisolid compacts (MLSC) of RLX for improved dissolution in immediate-release tablet formulations. Preliminary trials on selection of excipients were performed. Fourier transform infrared spectra illustrated no interaction between drug and MLSC powder. The X-ray diffraction studies demonstrated the transformation of the crystalline nature of drug into partial amorphous state in MLSC. After all experimental results on selection of excipients were analyzed, the final tablet formulation was derived and manufactured. The results of an in-vitro drug release study from the selected batch illustrated a remarkable improvement in the dissolution rate as compared to reference product. An accelerated stability study as per the ICH Q1 (R2) guideline of the optimized batch was performed for six months and showed no significant change in critical quality attributes of formulation. |
|---|